{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:05:08Z","timestamp":1780524308117,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004589","name":"French Institute for Public Health Surveillance (Institut de Veille Sanitaire)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004589","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lille 2 University of Health and Law"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.vaccine.2016.03.020","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T11:20:20Z","timestamp":1458386420000},"page":"2240-2250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France"],"prefix":"10.1016","volume":"34","author":[{"given":"H\u00e9lo\u00efse","family":"Lecocq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Parent du Ch\u00e2telet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"L\u00e9vy-Bruhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Dervaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.03.020_bib0240","unstructured":"European Centre for Disease Prevention and Control. Annual epidemiological report 2013. Stockholm. Available from \u3008http:\/\/www.ecdc.europa.eu\/en\/publications\/_layouts\/forms\/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=989\u3009; 2014, 260p [accesed 03.07.15]."},{"key":"10.1016\/j.vaccine.2016.03.020_bib0245","first-page":"25","article-title":"Les infections invasives \u00e0 m\u00e9ningocoques en France en 2012: principales caract\u00e9ristiques \u00e9pid\u00e9miologiques","volume":"1\u20132","author":"Barret","year":"2014","journal-title":"Bull Epidemiol Hebd"},{"issue":"6","key":"10.1016\/j.vaccine.2016.03.020_bib0250","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2016.03.020_bib0255","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"17\u201319","key":"10.1016\/j.vaccine.2016.03.020_bib0260","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.03.020_bib0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","author":"O\u2019Ryan","year":"2014","journal-title":"Drugs"},{"issue":"29","key":"10.1016\/j.vaccine.2016.03.020_bib0270","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1016\/j.vaccine.2007.04.071","article-title":"Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis","volume":"25","author":"De Wals","year":"2007","journal-title":"Vaccine"},{"issue":"7385","key":"10.1016\/j.vaccine.2016.03.020_bib0275","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"Br Med J"},{"issue":"9960","key":"10.1016\/j.vaccine.2016.03.020_bib0280","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0285","series-title":"Surveillance des infections invasives \u00e0 m\u00e9ningocoque en France m\u00e9tropolitaine en 2005. \u00c9valuation quantitative par la m\u00e9thode de capture-recapture \u00e0 trois sources.","first-page":"43","author":"Berger","year":"2010"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0290","unstructured":"NICE. Bacterial meningitis and meningococcal septicemia in children\u2014clinical guideline, Available from \u3008http:\/\/www.nice.org.uk\/guidance\/cg102\/resources\/guidance-bacterial-meningitis-and-meningococcal-septicaemia-pdf\u3009; 2010 [accessed 03.07.15]."},{"issue":"4","key":"10.1016\/j.vaccine.2016.03.020_bib0295","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1542\/peds.2006-0281","article-title":"Multicenter surveillance of invasive meningococcal infections in children","volume":"118","author":"Kaplan","year":"2006","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.vaccine.2016.03.020_bib0300","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/adc.2007.131862","article-title":"Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock","volume":"94","author":"Buysse","year":"2009","journal-title":"Arch Dis Child"},{"issue":"9","key":"10.1016\/j.vaccine.2016.03.020_bib0305","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.vaccine.2016.03.020_bib0310","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis Off Publi Infect Dis Soc Am"},{"issue":"9816","key":"10.1016\/j.vaccine.2016.03.020_bib0315","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2016.03.020_bib0320","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"9869","key":"10.1016\/j.vaccine.2016.03.020_bib0325","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2016.03.020_bib0330","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"J Am Med Assoc"},{"issue":"15","key":"10.1016\/j.vaccine.2016.03.020_bib0335","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"Can Med Assoc J (J Assoc Med Can)"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0340","unstructured":"Committee for Medicinal Products for Human Use. Assessment report. Bexsero. Procedure no. EMEA\/H\/C\/002333. European Medicines Agency, Available from \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002333\/WC500137883.pdf\u3009; 2012, 102p. [accessed 03.07.15]."},{"issue":"45","key":"10.1016\/j.vaccine.2016.03.020_bib0345","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0350","series-title":"Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique \u00e0 la HAS. Guide m\u00e9thodologique.","first-page":"83","year":"2011"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0355","unstructured":"Agence Technique de l\u2019Information sur l\u2019Hospitalisation [Internet]. Available from \u3008http:\/\/www.atih.sante.fr\/\u3009; 2015 [accessed 03.07.15]."},{"key":"10.1016\/j.vaccine.2016.03.020_bib0360","unstructured":"Minist\u00e8re de l\u2019\u00e9ducation nationale et Minist\u00e8re de l\u2019enseignement sup\u00e9rieur et de la recherche. Rep\u00e8res et r\u00e9f\u00e9rences statistiques sur les enseignements, la formation et la recherch\u00e9, Available from \u3008http:\/\/media.education.gouv.fr\/file\/2008\/13\/0\/RERS-2008_34130.pdf\u3009; 2008 [accessed 03.07.15]."},{"key":"10.1016\/j.vaccine.2016.03.020_bib0365","unstructured":"Dervaux BLX, Van Cauteren D, Parent du Ch\u00e2telet I, L\u00e9vy-Bruhl D. Analyse co\u00fbt-efficacit\u00e9 de la vaccination contre les infections invasives \u00e0 m\u00e9ningocoque C, Available from \u3008www.hcsp.fr\/explore.cgi\/hcspr20090424_meningC.pdf\u3009; 2009 [accessed 03.07.15]."},{"key":"10.1016\/j.vaccine.2016.03.020_bib0370","unstructured":"Maingen\u00e9 A. Les structures pour enfants handicap\u00e9s en 2006: un d\u00e9veloppement croissant des services \u00e0 domicile. Resultats de l\u2019enqu\u00eate ES 2006, Available from \u3008http:\/\/www.drees.sante.gouv.fr\/IMG\/pdf\/er669.pdf\u3009; 2008, vol 669, 8p."},{"key":"10.1016\/j.vaccine.2016.03.020_bib0375","unstructured":"Maingen\u00e9 A. Les \u00e9tablissements pour adultes handicap\u00e9s:des capacit\u00e9s d\u2019accueil en hausse. R\u00e9sultats provisoires de l\u2019enqu\u00eate ES 2006, Available from \u3008http:\/\/www.drees.sante.gouv.fr\/les-etablissements-pour-adultes-handicapes-des-capacites-d-accueil-en-hausse,4318.html\u3009; 2008, vol 641, 8p."},{"key":"10.1016\/j.vaccine.2016.03.020_bib0380","series-title":"Cost-effectiveness thresholds","year":"2015"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0385","series-title":"Disability weights for diseases in the Netherlands","author":"Stouthard","year":"1997"},{"issue":"1","key":"10.1016\/j.vaccine.2016.03.020_bib0390","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/eurpub\/10.1.24","article-title":"Disability weights for diseases: a modified protocol and results for a Western European region","volume":"10","author":"Stouthard","year":"2000","journal-title":"Eur J Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2016.03.020_bib0395","doi-asserted-by":"crossref","first-page":"e65036","DOI":"10.1371\/journal.pone.0065036","article-title":"Meningococcal serogroup A, C, W(1)(3)(5) and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands","volume":"8","author":"Hepkema","year":"2013","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.vaccine.2016.03.020_bib0400","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0895-4356(02)00448-1","article-title":"The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison","volume":"55","author":"Oostenbrink","year":"2002","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2016.03.020_bib0405","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10198-011-0351-x","article-title":"Valuing EQ-5D using time trade-off in France","volume":"14","author":"Chevalier","year":"2013","journal-title":"Eur J Health Econ Health Econ Prev Care"},{"issue":"7","key":"10.1016\/j.vaccine.2016.03.020_bib0410","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2016.03.020_bib0415","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2016.03.020_bib0420","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"23","key":"10.1016\/j.vaccine.2016.03.020_bib0425","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0430","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.vaccine.2016.03.020_bib0435","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"37","key":"10.1016\/j.vaccine.2016.03.020_bib0440","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.37.19665-en","article-title":"Community outbreak of group B meningococcal disease in southwest France\u2014December 2008 to September 2009","volume":"15","author":"Delisle","year":"2010","journal-title":"Euro Surveill"},{"issue":"7","key":"10.1016\/j.vaccine.2016.03.020_bib0445","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2807\/esm.11.07.00635-en","article-title":"Prolonged outbreak of B meningococcal disease in the Seine-Maritime department, France, January 2003 to June 2005","volume":"11","author":"Rouaud","year":"2006","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0450","series-title":"A quadrivalent vaccine against serogroup b meningococcal disease: a costeffectiveness study. Health technology assessment (HTA)","author":"Hanquet","year":"2014"},{"issue":"42","key":"10.1016\/j.vaccine.2016.03.020_bib0455","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0460","unstructured":"Haut Conseil de la Sant\u00e9 Publique. Vaccination contre les infections invasives \u00e0 m\u00e9ningocoque B. Place du vaccin Bexsero, Available from \u3008http:\/\/www.hcsp.fr\/Explore.cgi\/avisrapportsdomaine?clefr=386 2013\u3009; 2013 [accessed 03.07.15]."},{"issue":"4","key":"10.1016\/j.vaccine.2016.03.020_bib0465","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1586\/14760584.2015.1015997","article-title":"Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine","volume":"14","author":"Brendish","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2016.03.020_bib0470","series-title":"Rapport int\u00e9rimaire de surveillance de la s\u00e9curit\u00e9 de la premi\u00e8re dose du vaccin contre le m\u00e9ningocoque de s\u00e9rogroupe B au Saguenay\u2013Lac-Saint-Jean","year":"2014"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16003315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16003315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T18:00:26Z","timestamp":1655316026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16003315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":47,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0264410X16003315"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}